Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (Harvard Apparatus Regenerative Technology or the Company), a clinical-stage...
Holliston, MA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (œHarvard Apparatus Regenerative Technology or the œCompany), a clinical-stage...
Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (œHarvard Apparatus Regenerative Technology or the œCompany), a clinical-stage...
HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (œHRGN or the œCompany), a clinical-stage biotechnology company developing the...
HOLLISTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) (œBiostage or the œCompany), a clinical-stage biotechnology company developing the technology to regenerate organs...
LONDON, April 10, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the 22nd Annual Needham Virtual Healthcare Conference at 9:30 am ET on April 19, 2023. nnA live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the COMPASS website. The replay of the webcast will be accessible for 30 days following the event. For more information, please visit ir.compasspathways.com. nnAbout COMPASS Pathways
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, is pleased to announce that it is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (COVID-19). The Company has applied for a provisional patent with the U.S. Patent and Trademark Office entitled “Use of Bucillamine in the Treatment of Infectious Diseases” (Serial No. 62/991,996).
Biostage’s lab-grown replacement esophagus candidate has been placed on a clinical hold by the FDA as the company works to field questions from the agency before beginning initial human testing.